MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

Filter by vocabulary: issues (multisite):

After more than two years of raging conflict in Syria, humanitarian assistance inside the country and in neighboring states hosting Syrian refugees remains far below massive and growing needs.

More >

The Iraqi Ministry of Health and its supporters should improve access to mental health care services for a population still reeling from decades of conflict, political instability, and social upheaval.

More >

In Niger, the deadly combination of malaria and malnutrition has created a vicious cycle that has a huge impact on some of the country's most vulnerable people.

More >

Since the start of the conflict in Mali in January 2012, hundreds of thousands of people have fled to other locations inside the country or to neighboring countries.

More >

MSF Teleconference on the humanitarian situation in Syria, conducted March 7, 2013

More >

After two years of extremely violent conflict that the UN estimates has killed more than 70,000, the people of Syria are mired in a humanitarian catastrophe.

More >

Unless damaging provisions are removed before negotiations are finalized, the TPP agreement is on track to become the most harmful trade pact ever for access to medicines in developing countries.

More >

This report specifically focuses on MSF’s work with Syrian refugees and other displaced populations in Lebanon, where MSF teams are providing urgent assistance and free-of-charge medical care among people now sheltering in Tripoli and in various locations of the Bekaa Valley.

More >

This report focuses on just some of the many factors that hamper the scaling up of DR-TB treatment—the limited availability and high cost of quality assured medicines for resistant strains of the disease, owing to an insecure market and insufficient demand; and the research questions that remain unsolved with existing medicines.

More >

Over the past half century, there have been unprecedented improvements in health outcomes, spurred in part by unparalleled scientific progress in the pharmaceutical sector. Yet access to the benefits of medical progress and scientific advancement has not been equitably shared and many innovation gaps remain.

More >

Pages